Elucidata, which makes software to support drug discovery, recently released a metabolomics analysis platform that includes machine learning technology.
The UK-based Dementia Discovery Fund is investing $1.3M in Immuneering's drug-discovery technology in search of new molecular entities for treating Alzheimer's.
With the Series B funding, Sytenkabio will consolidate its headquarters in Seoul, validate its technology, and look to expand into international markets.
Since 2015, the Regeneron Genetics Center has sequenced 250,000 exomes from phenotyped individuals, identifying "human knockouts" and other large-effect mutations.
Qrativ, a joint venture of Mayo Clinic and Nference, seeks new treatments for rare diseases by coupling Mayo research with publicly available genomic data sets.
The companies will share bioinformatics and NGS expertise to speed the identification of diseases, accelerate drug discovery, and find "genomic shields."
TwoXar will work with Stanford's Asian Liver Center to identify and validate computationally-derived drug candidates that target hepatocellular carcinomas.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
